

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0104 |
| Estimated average burden hours per response: | 0.5 |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | | | | | |
|--|---------|----------|---|--|---|---|--|
| 1. Name and Address of Reporting Person* <u>Gasser Elizabeth Anne</u> | | | 2. Date of Event Requiring Statement (Month/Day/Year) <u>06/02/2021</u> | | 3. Issuer Name and Ticker or Trading Symbol <u>TANDEM DIABETES CARE INC [TNDM]</u> | | |
| (Last) | (First) | (Middle) | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> Officer (give title below) <u>EVP, Chief Strategy Officer</u> | | | 5. If Amendment, Date of Original Filed (Month/Day/Year) | |
| C/O TANDEM DIABETES CARE, INC. 11075 ROSELLE STREET | | | 10% Owner Other (specify below) | | | 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person | |
| (Street) | (City) | (State) | (Zip) | | | | |
| SAN DIEGO | CA | | 92121 | | | | |

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|
| Common Stock | 975 | D | |

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|-----------------|---|----------------------------|--|--|---|
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | |
| Stock Option ⁽¹⁾ | (2) | (3) | Common Stock | 38,247 | 89.54 | D | |
| Stock Option ⁽¹⁾ | (4) | (3) | Common Stock | 13,761 | 82.34 | D | |
| Restricted Stock Unit ⁽¹⁾ | (5) | (5) | Common Stock | 5,962 | 0.0 | D | |
| Stock Option ⁽¹⁾ | (6) | (3) | Common Stock | 7,940 | 81.63 | D | |
| Restricted Stock Unit ⁽¹⁾ | (7) | (7) | Common Stock | 2,599 | 0.0 | D | |
| Performance Stock Unit ⁽¹⁾ | (8) | (8) | Common Stock | 2,599 | 0.0 | D | |

Explanation of Responses:

- Granted pursuant to the Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan").
- The date of grant of the option was 02/18/2020. 25% of the shares subject to the option vested on 02/18/2021 and the remainder vests in 36 equal monthly installments thereafter.
- The expiration date for these options is 10 years from the date of grant.
- The date of grant of the option was 05/27/2020. 25% of the shares subject to the option vested on 05/27/2021 and the remainder vests in 36 equal monthly installments thereafter.
- The date of Restricted Stock Unit ("RSU") grant was 05/27/2020. RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on the one year anniversary of the grant date, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter, subject to the terms of the 2013 Plan. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.
- The date of grant of the option was 05/18/2021. 25% of the shares subject to the option will vest on 05/18/2022 and the remainder vests in 36 equal monthly installments thereafter.
- The date of Restricted Stock Unit ("RSU") grant was 05/18/2021. RSU vest as to twenty-five percent (25%) of the total number of shares subject to the RSU on 05/15/2022, and the remaining shares shall vest in twelve (12) equal quarterly installments thereafter, subject to the terms of the 2013 Plan. Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2013 Plan.
- Each performance stock unit ("PSU") represents a contingent right to receive one share of Tandem Diabetes Care, Inc. (the "Company") common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2024 (the "Measurement Date"). The number of shares issued may range from 0% to 200% of the amount specified above, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSU's will vest.

Remarks:

s/ David B. Berger, Attorney-in-Fact for Elizabeth A. Gasser 06/10/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

The undersigned hereby constitutes and appoints David B. Berger, Leigh A. Vosseller, Karrie Rexford, Christina X. Sun, James W. Sytsma and Ryan (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer of Tandem Diabetes Care, Inc. (the "Company"), (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to complete and execute any such (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to the undersigned. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever that may be necessary or desirable to complete and execute any such action. The undersigned agrees that each such attorney-in-fact may rely entirely on information furnished orally or in writing by the undersigned to the extent of such information.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4s and 5s with respect to the Company. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 3rd day of June, 2021.

By:

Name: Elizabeth A. Gasser